ArticleFrontiers in bioinformatics2026
Comparative transcriptomics and computational drug discovery identify ASPM as a key oncogenic driver and therapeutic target in hepatocellular carcinoma.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy that necessitates the identification of robust biomarkers across diverse populations to enhance diagnostic and prognostic precision. This study aimed to identify clinically relevant biomarkers and potential therapeutic targets through integrative transcriptomic and computational analyses. Methods: A comparative transcriptomic analysis was performed on 724 HCC samples obtained from four independent cohorts (United States, South Korea, France, and Taiwan). Differential expression and survival analyses, including Kaplan-Meier estimation, were conducted to evaluate clinical significance. Functional enrichment analysis was used to explore biological roles. Structural modeling, molecular docking, 100-ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and Results: Abnormal Spindle Microtubule Assembly (ASPM) was consistently overexpressed across all cohorts and significantly associated with poor overall survival. Functional analyses indicated its involvement in mitotic spindle organization and homologous recombination-mediated DNA repair. Among screened compounds, Mol-7424 exhibited stable binding within the ASPM calponin domain, favorable binding free energy, and promising pharmacokinetic properties. Lipid bilayer simulations further supported its membrane permeability and potential cellular uptake. Discussion: These findings highlight ASPM as a prognostic biomarker and potential therapeutic target in HCC. Mol-7424 emerges as a promising lead compound; however, its efficacy requires validation through
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.